What question did this study set out to answer?

This trial aims to explore the role of ctDNA in adapting adjuvant chemotherapy for early-stage colon cancer patients.

October 12, 2022ONCOLOGYOpen Access

Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US

View Full Paper

Ask AI

Bookmark

Authors

ISIbrahim Halil SahinUniversity of Pittsburgh Medical Center

Discussion

Member takes

Implication

Randomized trial investigates ctDNA-guided adjuvant therapy in early-stage colon cancer, suggesting important treatment adjustments for better outcomes.

Key Points

This trial aims to explore the role of ctDNA in adapting adjuvant chemotherapy for early-stage colon cancer patients.
Prospective phase 2/3 randomized trial with patients having resected colon cancer.
Patients with negative postoperative ctDNA were randomized to immediate treatment or delayed therapy based on ctDNA results.
Cohort B patients were directly enrolled with positive ctDNA for further randomization between two treatment arms.
Cohort A primary endpoint is time to positive ctDNA status for phase 2 and disease-free survival for phase 3.
Cohort B aims for disease-free survival with a superiority design across both phases.

Cite This Study

Ibrahim Halil Sahin (2022) studied this question.

synapsesocial.com/papers/6a5ee7da9e99e7407a7e3fca https://doi.org/10.46883/2022.25920976

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial investigates ctDNA-guided adjuvant therapy in early-stage colon cancer, suggesting important treatment adjustments for better outcomes.

Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US

Discussion

Member takes

Implication

Key Points

Cite This Study

Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider